Osimertinib significantly prolonged OS compared with previous standard-of-care first-line therapies for patients with locally advanced or metastatic, EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.
Osimertinib (Tagrisso, AstraZeneca) — a third-generation, irreversible EGFR tyrosine kinase inhibitor — is already approved in the United States for first-line treatment of EGFR-mutated metastatic NSCLC. It is the only therapy to confer a significant OS benefit in this setting.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.